Plain-English translation of NCT02541383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a new medication, combined with three standard chemotherapy drugs (bortezomib, thalidomide, and dexamethasone) in people newly diagnosed with multiple myeloma. About half the participants received the standard three-drug treatment alone, while the other half received the same treatment plus . After chemotherapy and stem cell transplant, patients who responded well were randomly assigned to either continue taking or simply be watched without additional treatment.
Multiple myeloma is a serious blood cancer, and researchers wanted to see whether adding this new medication to existing treatment could help patients live longer and have better control of their disease.
Participants went through a 28-day screening phase first, then received six cycles of chemotherapy treatment (each cycle lasting 4 weeks). After completing chemotherapy and undergoing a stem cell transplant, those who responded well were randomly assigned to either continue with additional medication for maintenance or observation without treatment. The entire study lasted about 138 weeks (roughly 2.5 years) per participant, with disease assessments every 4 weeks during the first phase and every 8 weeks during the second phase, plus 2 years of follow-up visits.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Belgium